Type 2 diabetes mellitus (DM2) is a serious medical and social problem, which is associated with the epidemic growth rate of morbidity and the development of chronic complications leading to early disability, reduced quality of life and early death of patients. To date, it has been established that the optimal hypoglycemic therapy with the achievement of target metabolic parameters from the moment of diagnosis of type 2 diabetes until the end of life is the basis for the prevention of diabetic complications. Therapy with simultaneous action on various disorders is associated with great hypoglycemic potential and the ability to maintain glycemic control as the disease progresses. The article discusses the possibilities of metformin, sulfonylurea drugs, and fixed combinations. A clinical case of DM2 that developed in adulthood is presented. The patient was prescribed combination therapy with metformin and glibenclamide (Metglib Force). The possibility of this patient having MODY3 diabetes, which is characterized by good therapeutic effect of sulfonylurea drugs and specifically glibenclamide, is discussed.

Keywords: MODY3 type diabetes mellitus, sulfonylurea drugs, glibenclamide, glycated hemoglobin, type 2 diabetes mellitus, metformin